Formation and removal of alpha-synuclein aggregates in cells exposed to mitochondrial inhibitors

He-Jin Lee1, Soon Young Shin, Chan Choi

  • 1Parkinson's Institute, Sunnyvale, California 94089, USA.

Insights

Impaired mitochondrial function can trigger alpha-synuclein aggregation, forming Lewy body-like inclusions in Parkinson's disease. Restoring mitochondrial metabolism can reverse this process.

Area of Science:

  • Neuroscience
  • Cell Biology
  • Biochemistry

Background:

  • Mitochondrial dysfunction is linked to Parkinson's disease (PD).
  • The role of mitochondrial defects in Lewy body formation, a key PD pathology, remains unclear.

Purpose of the Study:

  • To investigate the impact of mitochondrial electron-transport chain (ETC) inhibitors on alpha-synuclein aggregation.
  • To explore the relationship between mitochondrial dysfunction and the formation of Lewy body-like inclusions.

Main Methods:

  • Cells were treated with ETC inhibitors (rotenone, oligomycin) to induce mitochondrial dysfunction.
  • Alpha-synuclein aggregation was assessed using biochemical assays and microscopy.
  • ATP levels, aggregate co-localization, and thioflavin S staining were analyzed.

Main Results:

  • Inhibitors of mitochondrial complex I (rotenone) and ATP synthase (oligomycin) increased alpha-synuclein aggregation and reduced ATP levels.
  • Microscopy revealed the formation of perinuclear inclusions positive for ubiquitin and proteasome markers.
  • Inclusions exhibited amyloid-like properties (thioflavin S-positive) and disappeared upon restoration of mitochondrial function.

Conclusions:

  • Impaired mitochondrial function can initiate the formation of alpha-synuclein inclusions.
  • These inclusions resemble Lewy bodies and their formation is linked to mitochondrial defects.
  • Restoring mitochondrial metabolism offers a potential pathway for reversing alpha-synuclein aggregation in PD.